Reconfirmation of Market Guidance and AGM Q&A

Summary by AI ^BETAClose X

SkinBioTherapeutics plc has confirmed that its trading for the new financial year has started positively and anticipates reporting full-year 2026 results in line with market expectations, which include revenue of £6.2 million and adjusted EBITDA of £0.7 million. The company also provided a Q&A for shareholders regarding the upcoming Annual General Meeting.

Disclaimer*

SkinBioTherapeutics PLC

18 December 2025

A blue text on a white background Description automatically generated

SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Group" or the "Company")

Reconfirmation of Market Guidance and AGM Shareholder Information

18 December 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, confirms that overall trading of the Group has started very positively for the new financial year. Consequently, the Board still anticipates reporting 2026 full year numbers in line with market expectations*.

In addition, in response to some shareholder questions about the upcoming AGM, the Directors have provided a Q&A within the Shareholder Circulars section of the Shareholder Information page [Here].

* Market expectations for the year ending 30 June 2026: revenue of £6.2 million and adjusted EBITDA of £0.7 million

-Ends-

For more information please contact:

SkinBioTherapeutics plc

Stuart J. Ashman, CEO
Emily Bertram, Group Finance Director

+44 (0) 191 495 7325

Singer Capital Markets (Nominated Adviser & Broker)

Philip Davies
James Todd
Patrick Weaver

+44 (0) 020 7496 3000

Vigo Consulting (financial press)

Rozi Morris, Melanie Toyne-Sewell

+44 (0) 20 7390 0230

SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix^®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix^®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix^® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END